THIS IS AN ASPIRE PHARMA WEBSITE PAGE INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY
Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to Aspire Pharma Ltd on +44 (0)1730 231148.

For more information about products within the Pathway Portfolio, please click here for prescribing information

Respiratory

The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.

Each product in the portfolio has its own key offerings, ranging from:

  • a full range of strengths available1
  • a first strength to market1
  • simpler dosing which may help some patients with concordance and compliance1-2
  • the first brand to market1

All of which create a wider offering to patients.

Pathway to Partnership:

Trusted Brands:

  • Bioequivalent to brand originators3
  • Available from mainline wholesalers

Bespoke Support:

  • Price guarantee
  • Individualised rebates on request
Contact a member of our team

Please click here for Combisal® prescribing information

Combisal® (salmeterol/fluticasone) inhalers

Combisal® (salmeterol/fluticasone) is a pressurised metered dose inhaler (pMDI) for the regular treatment of asthma where use of a combination product (long-acting ß2-agonist and inhaled corticosteroid) is appropriate for:

  • patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short- acting β2 agonist

or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist4

  • Bioequivalent to Seretide® pMDI (salmeterol/fluticasone) across all three strengths3

  • Licensed in both children (25μg/50μg) and adults4**

  • Meets the ups and downs of cost-effective asthma management: flexibility and consistency for patients and prescribers, every step of the way

CONTACT US TO REQUEST
A COST SAVING REPORT

Save up to 55% on the cost of category C (salmeterol/fluticasone pMDI) on the UK Drug Tariff1

Combisal® could reduce the average ICB prescribing cost of salmeterol/fluticasone by an average of £113,399 per annum, saving up to £4,082,375 annually across the NHS5*.

Please find below materials, which you may find useful for your own reference or to assist with your prescribing. If you would like to order printed versions of any of the materials listed below, please click here to contact one of our representatives.

Patient materials

The following materials can be given to patients being prescribed Combisal®

Patient Tear Off Pad

RightBreathe® – How to use your Metered dose inhaler

The following RightBreathe® Training video demonstrates how to use a pressurised metered dose inhaler (pMDI), which can be used with your patients in your clinics6.

The video below was created by and is owned by RightBreathe®. Aspire Pharma is not responsible for the content of the video.

References:

*Average ICB is based on 4 x Moving Quarterly Turnover (MQT) divided by 36 ICB’s

**Combisal® 25/50μg is licensed in children aged 4 and over. All three strengths licensed in adults and adolescents 12 years and older. Combisal 25μg/50μg is not appropriate for adults and adolescents with severe asthma.

  1. UK Drug Tariff (Accessed June 2026)
  2. Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
  3. Data on file 1010422379 v 5.0 March 2025 Combisal bioequivalence
  4. Combisal® SmPC (Accessed June 2026)
  5. MAT-UK-EPI-0139-1 Pathway Portfolio cost savings, GPPLPD Date Range: Jan-26 – Mar-26
  6. RightBreathe© Training Video https://www.rightbreathe.com/medicines/2365/ (Accessed June 2026)

MAT-UK-XLP-0032-1 | June 2026